Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Hip fractures in users of first- vs. second-generation bisphosphonates.

Mamdani M, Kopp A, Hawker G.

Osteoporos Int. 2007 Dec;18(12):1595-600.

PMID:
17767369
2.

[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].

Netelenbos JC.

Ned Tijdschr Geneeskd. 2001 Jul 14;145(28):1336-8. Review. Dutch.

PMID:
11484428
3.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
4.

Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

Bilezikian JP.

Am J Med. 2009 Feb;122(2 Suppl):S14-21. doi: 10.1016/j.amjmed.2008.12.003. Review.

PMID:
19187808
5.

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Ettinger MP.

Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.

PMID:
14557222
6.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
7.

[Treatment of osteoporosis by risedronate-- speed, efficacy and safety].

Giljević Z, Vlak T.

Reumatizam. 2006;53(2):66-71. Review. Croatian.

PMID:
17580558
8.

Risedronate prevents hip fractures, but who should get therapy?

Deal CL.

Cleve Clin J Med. 2002 Dec;69(12):964, 968-70, 973-6. Review.

PMID:
12546269
9.

Drug insight: Bisphosphonates for postmenopausal osteoporosis.

Chapurlat RD, Delmas PD.

Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. Review.

PMID:
16932286
10.

Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.

Sebba AI.

Clin Ther. 2008 Mar;30(3):443-52. doi: 10.1016/j.clinthera.2008.03.008. Review. Erratum in: Clin Ther. 2008 Jun;30(6):1177-8.

PMID:
18405784
11.

Treatment of osteoporosis with bisphosphonates.

Watts NB.

Rheum Dis Clin North Am. 2001 Feb;27(1):197-214. Review.

PMID:
11285996
12.

Preventing osteoporosis-related fractures: an overview.

Gass M, Dawson-Hughes B.

Am J Med. 2006 Apr;119(4 Suppl 1):S3-S11. Review.

PMID:
16563939
13.

[Osteoporosis in the elderly--diagnosis and treatment].

Gärtner R.

MMW Fortschr Med. 2005 Feb 17;147(7):33, 35-6. Review. German.

PMID:
18441582
14.

Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.

Inderjeeth CA, Foo AC, Lai MM, Glendenning P.

Bone. 2009 May;44(5):744-51. doi: 10.1016/j.bone.2008.12.003. Review.

PMID:
19130909
16.
17.

Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.

Iwamoto J, Matsumoto H, Takeda T.

Curr Med Res Opin. 2008 May;24(5):1379-84. doi: 10.1185/030079908X297321 . Review.

PMID:
18384711
18.
19.

[Progress in external hip protectors].

Koike T.

Clin Calcium. 2006 Sep;16(9):1493-99. Review. Japanese.

PMID:
16951474
20.

Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.

Kherani RB, Papaioannou A, Adachi JD.

Drug Saf. 2002;25(11):781-90. Review.

PMID:
12222989
Items per page

Supplemental Content

Support Center